- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04294589
Evaluation of NETs in Patients With Solid Cancers Associated With a High Risk of Venous Thromboembolic Events (Flownet)
Evaluation of Neutrophil Extracellular Traps (NETs) by Flow Cytometry in Patients With Solid Cancers Associated With a High Risk of Venous Thromboembolic Events
Venous Thromboembolic Events (ETVs) are the second leading cause of death (9.2% of causes of death) in cancer patients after tumor progression (1). Indeed, cancer is associated with a 4 to 7-fold risk of ETV during chemotherapy (2). This complication is observed in 20% of cancer patients (3), and is sometimes an inaugural manifestation of cancer. This risk is particularly increased during the first 3 months after cancer diagnosis (4).
A biomarker correlated with the occurrence of ETVs would make it possible to target patients at high risk of thrombosis who could benefit from primary thromboprophylaxis, thus avoiding the complications, particularly haemorrhagic, and the additional costs associated with the long-term diagnostic and therapeutic management of ETVs. The investigator has implemented in the laboratory an innovative approach to the detection and quantification of circulating NETs by flow cytometry (FCM) allowing the routine determination of NETs. Therefore the investigator propose to assess NETs by CMF in a cohort of cancer patients with a very high risk of ETVs (pancreatic cancer, gastric cancer and colon cancer).
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studiekontakt
- Namn: Valérie BARDET, PhD
- Telefonnummer: (+33) 1.49.09.54.13
- E-post: valerie.bardet@aphp.fr
Studieorter
-
-
Haut De Seine
-
Boulogne-Billancourt, Haut De Seine, Frankrike, 92100
- Rekrytering
- Ambroise Paré Hospital
-
Kontakt:
- Valerie Barder, PhD
- Telefonnummer: +33 149095413
- E-post: valerie.bardet@aphp.fr
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Male or Female over 18 years of age (≥18),
- Patient with pancreatic, gastric or colorectal cancer,
- Patient with a high risk of ETV,
- Patient on the first line of treatment or relapsing after a period of complete remission,
- Patient affiliated to a social security system or CMU.
Exclusion Criteria:
- Patient who has had an ETV in the 3 months prior to inclusion,
- Patient with a life expectancy of less than 3 months,
- Patient with an anticoagulation placement,
- Known pregnant or breastfeeding woman,
- Patient under guardianship or curatorship.
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Show that the NETs rate is higher at diagnosis in solid cancer patients with ETV within 4 months of diagnosis compared to patients without ETV
Tidsram: 16 months
|
At the end of the study, after a minimum clinical follow-up of 4 months, the frequency of ETVs will be correlated to the NET rate measured in univariate and multivariate analysis (including also the following thrombotic risk factors: neutrophil levels, platelet levels, D-dimers, factor VIII, procoagulant activity of PM and body mass index).
|
16 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Determine a threshold of NETs that optimizes management based on the consequences of classification errors through decision analysis
Tidsram: 16 months
|
The choice of an optimal threshold of NETs (sensitivity, specificity, likelihood ratio) will be determined by decision analysis using a decision tree combining probabilities of events and costs associated with fair (true positive, true negative) and erroneous (false positive, false negative) decisions.
|
16 months
|
Explore the possibility of a prognostic VTE score integrating the NET rate and other clinical and biological parameters measured at the time of cancer diagnosis
Tidsram: 16 months
|
The choice of an optimal threshold of NETs (sensitivity, specificity, likelihood ratio) will be determined by decision analysis using a decision tree combining probabilities of events and costs associated with fair (true positive, true negative) and erroneous (false positive, false negative) decisions.
|
16 months
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Valérie BARDET, PhD, hematology immunology transfusion Service, Ambroise Pare hospital
Publikationer och användbara länkar
Allmänna publikationer
- Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007 Mar;5(3):632-4. doi: 10.1111/j.1538-7836.2007.02374.x. No abstract available.
- Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006 Feb 27;166(4):458-64. doi: 10.1001/archinte.166.4.458.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- APHP190640
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Magcancer
-
Universitätsklinikum Hamburg-EppendorfCentre Hospitalier Universitaire de Nice; Olympus Corporation; Keio University och andra samarbetspartnersAvslutadGastric Focal LesionFrankrike
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AvslutadRoux-en-Y Gastric Bypass | Bariatrisk kirurgi | Vertikal sleeve gastrectomy | Magbandning | Bypass, GastricFörenta staterna
-
RSP Systems A/SAvslutad
-
State University of New York - Upstate Medical...AvslutadGastric Bypass StatusFörenta staterna
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)IndragenGastric Bypass-kirurgi
-
Medtronic - MITGAvslutad
-
DuomedAktiv, inte rekryterandeFetma | Gastrektomi | Roux-en-Y Gastric Bypass | Mini Gastric BypassBelgien
-
Wageningen UniversityRijnstate HospitalOkändRoux-en-Y Gastric BypassNederländerna
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaAvslutadRoux en Y Gastric BypassFörenta staterna
-
Olympus Corporation of the AmericasUnity Health TorontoAvslutad